Patents by Inventor Sanjay K. Pandey
Sanjay K. Pandey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230174987Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.Type: ApplicationFiled: July 21, 2022Publication date: June 8, 2023Applicants: Ionis Pharmaceuticals, Inc., University of RochesterInventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
-
Publication number: 20200362353Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.Type: ApplicationFiled: December 20, 2019Publication date: November 19, 2020Applicants: Ionis Pharmaceuticals, Inc., University of RochesterInventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
-
Publication number: 20180163209Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.Type: ApplicationFiled: July 24, 2017Publication date: June 14, 2018Applicants: Ionis Pharmaceuticals, Inc., University of RochesterInventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
-
Patent number: 9765338Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.Type: GrantFiled: July 30, 2015Date of Patent: September 19, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
-
Publication number: 20160304877Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.Type: ApplicationFiled: August 11, 2014Publication date: October 20, 2016Applicant: Ionis Pharmaceuticals, Inc.Inventors: Eric E. Swayze, Sanjay K. Pandey, Robert A. MacLeod, C. Frank Bennett, Susan M. Freier
-
Publication number: 20160068845Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.Type: ApplicationFiled: July 30, 2015Publication date: March 10, 2016Applicants: UNIVERSITY OF ROCHESTER, ISIS PHARMACEUTICALS, INC.Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
-
Publication number: 20140275207Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Sanjay K. Pandey, Robert McKay, Sanjay Bhanot, Xing-Xian Yu
-
Patent number: 8580948Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: GrantFiled: June 22, 2012Date of Patent: November 12, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Kenneth W. Dobie, Sanjay Bhanot, Robert McKay, Sanjay K. Pandey
-
Patent number: 8541387Abstract: Disclosed herein are compounds and methods for decreasing SMRT and treating metabolic and/or cardiovascular diseases in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to SMRT include obesity, diabetes, dyslipidemia, and hypothyroidism.Type: GrantFiled: May 21, 2009Date of Patent: September 24, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay K. Pandey, Sanjay Bhanot, Eric G. Marcusson, Susan M. Freier
-
Publication number: 20130237585Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.Type: ApplicationFiled: July 19, 2011Publication date: September 12, 2013Applicants: UNIVERSITY OF ROCHESTER, ISIS PHARMACEUTICALS, INC.Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
-
Publication number: 20130030036Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: ApplicationFiled: June 22, 2012Publication date: January 31, 2013Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
-
Patent number: 8227593Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: GrantFiled: August 20, 2010Date of Patent: July 24, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Kenneth W. Dobie, Sanjay Bhanot, Robert McKay, Sanjay K. Pandey
-
Patent number: 8202981Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.Type: GrantFiled: January 19, 2011Date of Patent: June 19, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
-
Publication number: 20110152351Abstract: Disclosed herein are compounds and methods for decreasing SMRT and treating metabolic and/or cardiovascular diseases in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to SMRT include obesity, diabetes, dyslipidemia, and hypothyroidism.Type: ApplicationFiled: May 21, 2009Publication date: June 23, 2011Inventors: Sanjay K. Pandey, Sanjay Bhanot, Eric G. Marcusson, Susan M. Freier
-
Publication number: 20110112171Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart diseaseby administration of antisense compounds targeted to PTPRU.Type: ApplicationFiled: January 19, 2011Publication date: May 12, 2011Applicant: Isis Pharmaceuticals, Inc.Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
-
Patent number: 7897583Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.Type: GrantFiled: May 24, 2006Date of Patent: March 1, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
-
Publication number: 20100311824Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box 01A are provided, in particular, for methods of treating diabetes.Type: ApplicationFiled: August 20, 2010Publication date: December 9, 2010Applicant: ISIS PHARMACEUTICALS, INC.Inventors: KENNETH W. DOBIE, SANJAY BHANOT, ROBERT MCKAY, SANJAY K. PANDEY
-
Patent number: 7807649Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: GrantFiled: April 23, 2007Date of Patent: October 5, 2010Assignee: Isis Pharmaceuticals, Inc.Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
-
Publication number: 20080280845Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.Type: ApplicationFiled: May 24, 2006Publication date: November 13, 2008Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
-
Publication number: 20080153767Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: ApplicationFiled: April 23, 2007Publication date: June 26, 2008Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey